Tag: preclinical

Modulight Spotlights: LASER-SHARP RESEARCH – November 2025

Laser-sharp Research / cancer, chemotherapy, drug delivery, glioblastoma, in vitro, laser-sharp research, ML8500, multidrug resistance, photoactivated chemotherapy, Photoimmunotherapy, preclinical, therapy resistance, tumor, University of Maryland, verteporfin

Modulight Spotlights: LASER-SHARP RESEARCH – November 2025 We are delighted to highlight new exciting study by Rahman et al. from Dr. Huang-Chiao Huang’s lab at University of Maryland. Multidrug resistance remains a significant barrier to successful chemotherapy outcomes for cancer patients, often caused by active pumping of chemotherapeutics outside of cancer cells. Hence, the team [...]

Modulight Spotlights: LASER-SHARP RESEARCH – November 2025 Read More »

Modulight Spotlights: LASER-SHARP RESEARCH – October 2025

Laser-sharp Research / breast cancer, immunotherapy, laser-sharp research, ML7710, myeloma, oral cancer, Photoimmunotherapy, preclinical, T cells

This month we are highlighting exciting findings by S. Takao et al. from Hisataka Kobayashi’s lab at the National Cancer Institute, NIH. Published in Cancer Letters, the study shows that near-infrared photoimmunotherapy can destroy cancer cells by targeting intercellular adhesion molecule-1.

Modulight Spotlights: LASER-SHARP RESEARCH – October 2025 Read More »

Modulight Spotlights: LASER-SHARP RESEARCH – April 2023

Laser-sharp Research / Combination therapy, combinationtherapy, immunotherapy, in vitro, in vivo, laser-sharp research, ML6600, MLAKIT, Photoimmunotherapy, preclinical

Modulight Spotlights: LASER-SHARP RESEARCH – April 2023 Read More »

Modulight Spotlights: LASER-SHARP RESEARCH – September 2021

Laser-sharp Research / immunotherapy, laser-sharp research, lasers in science, ML7710, Modulight in science, novel treatments, Photoimmunotherapy, preclinical

Modulight Spotlights: LASER-SHARP RESEARCH – September 2021 Read More »

Photothermal therapy with platinum nanoparticles

Application Note / 808nm, brain cancer, ex vivo, in vitro, ML6600, MLAKIT, Niels Bohr Institute, NIR, ovarian cancer, photothermal therapy, platinum nanoparticles, preclinical, University of Copenhagen

Photothermal therapy efficiency Human ovarian cancer cells were plated on Petri dishes and incubated with platinum nanoparticles of varying sizes between 30 and 70 nm. After 24-hour incubation, irradiation was performed using a Modulight ML6600 laser at 808 nm together with an illumination kit (MLAKIT) tailored for Petri dish illumination. A small area of the dish

Photothermal therapy with platinum nanoparticles Read More »

Virus-like particle-drug conjugates induce protective, long-lasting adaptive anti-tumor immunity in the absence of specifically targeted tumor antigens

Scientific papers / 690 nm, immune checkpoints, in vitro, MLAKIT, preclinical, tumor, Uveal Melanoma

Published in: Cancer Immunology Research Authors: Rhonda C Kines, Cynthia D Thompson, Sean Spring, Zhenyu Li, Elisabet de los Pinos, Stephen Monks, John T Schiller Related application note: Vision-sparing targeted phototherapy for uveal melanoma

Virus-like particle-drug conjugates induce protective, long-lasting adaptive anti-tumor immunity in the absence of specifically targeted tumor antigens Read More »

Vascular-targeted phototherapy study for prostate cancer

Application Note / customer, in vivo, Memorial Sloan Kettering Cancer Center, ML7710, MSKCC, preclinical, prostate cancer, Weizmann Institute of Science

Study protocol Related Modulight products and Services ML7710 – Laser device suited for pre-clinical and clinical applications » Related Publications WST11 Vascular Targeted Photodynamic Therapy Effect Monitoring by Multispectral Optoacoustic Tomography (MSOT) in Mice Volker Neuschmelting, Kwanghee Kim, Jaber Malekzadeh-Najafabadi, Sylvia Jebiwott, Jaya Prakash, Avigdor Scherz, Jonathan A Coleman, Moritz F Kircher, Vasilis Ntziachristos Theranostics, 2018,

Vascular-targeted phototherapy study for prostate cancer Read More »

In vitro illumination using ML8500: osmium-based anticancer photosensitizer with highest hypoxic activity reported to date

Application Note / drug discovery, in vitro, ML8500, photosensitizer, preclinical, University of Texas at Arlington

Sherri McFarland discussing how ML8500 is supporting her research Study protocol to determine wavelength, fluence, and irradiance activities of Os-4T: Key observations Illumination parameters significantly affected the phototoxicity of Os-4T. The green light (525 nm) was more effective than the red light (630 nm) at lower fluences, while the maximal potency was

In vitro illumination using ML8500: osmium-based anticancer photosensitizer with highest hypoxic activity reported to date Read More »

Heat shock protein 90-targeted photodynamic therapy enables treatment of subcutaneous and visceral tumors

Scientific papers / 690 nm, breast cancer, HSP90, in vitro, ML7710, ML8500, PDT, Photodynamic therapy, preclinical, targeted therapies, verteporfin

Published in: Communications Biology Authors: Kensuke Kaneko, Takuya Osada, Michael A. Morse, William R. Gwin, Joshua D. Ginzel, Joshua C. Snyder, Xiao-Yi Yang, Cong-Xiao Liu, Márcio A. Diniz, Khaldon Bodoor, Philip F. Hughes, Timothy AJ. Haystead, H. Kim Lyerly

Heat shock protein 90-targeted photodynamic therapy enables treatment of subcutaneous and visceral tumors Read More »